Podcast
MLS Talk: Tom Caravela, Lusine Kodagolian
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools
Summary
- Current Value Frameworks (VFs) have limitations and do not meet HARMONY's ambitions for assessing the therapeutic/clinical value of innovative health technologies.
- There is a need for a cross-stakeholder agreement on the definition of "value," which varies among patients, clinicians, and payers.
- Involvement of current stakeholders and external experts in RWE, patient preferences, health economics, and pricing decisions is crucial.
- After defining "value," a new Health Alliance Value Framework (HAVF) should be designed based on task force outcomes in Supplemental Materials.
- Validation of the HAVF should be conducted through field testing using the HARMONY network.
In 2012, costs associated with hematologic malignancies (HMs) in the European Union (EU) reached €12 billion accounting for 8% of total EU cancer costs (€143 billion). This consisted of direct healthcare costs of €7·3 billion, productivity losses of €3.6 billion, and informal care costs of €1 billion.
It is evident that HMs are not only a major economic burden but also a major source of mortality and morbidity, with approximately 44 000 new cases in Europe per year. Of note, in 2020, there were 311 594 deaths because of leukemia worldwide. In the same year, leukemia mortality ranged from 5 cases per 100 000 inhabitants in Malta to 17.7 in Cyprus, with the EU27 average at 9.1....
clinical value framework, hematology, Healthcare Alliance for Resourceful Medicine, Offensive Against Neoplasms in hematology, patient-reported outcomes, HARMONY, analysis
Related Topics
You May Also Like
MLS Talk: Tom Caravela, Lusine Kodagolian
Podcast
MSL Talk: Tom Caravela, Linda Taylor
The 3 “Knows” of Effective Scientific Communication
Podcast
MSL Talk: Tom Caravela, Tim Bialekki , Alec McCarthy
New ‘Social’ Technology to Help Identify KEY Trends for Medical Affairs
Podcast
MSL Talk: Tom Caravela, Amy Misnik
The Importance of Networking for MSLs with Amy Misnik
Article
Anushka Walia, Alyson Haslam, Vinay Prasad
FDA validation of surrogate endpoints in oncology: 2005–2022
Article
Cheryl Ho, MD, Howard J. Lim, MD, Dean A. Regier, PhD